ArticleInternational journal of colorectal disease2005
Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease.
Article in International journal of colorectal disease, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Inflammatory bowel disease and extracellular matrix: when victim becomes double agent.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Exploring the role of intestinal microbiota in mitigating acute radiation-induced intestinal injury through high-energy X-ray FLASH radiotherapy via metagenomic analysis.Frontiers in microbiology · 2025Article
- Mucin glycans and their degradation by gut microbiota.Glycoconjugate journal · 2023Review
- Role of heparanase in sepsis‑related acute kidney injury (Review).Experimental and therapeutic medicine · 2023Review
- Colonic mucosal biopsy location can not affect the results of mucosal metabolomics and mucosal microbiota analysis in IBS.Frontiers in medicine · 2023Article
- Role of heparinase in the gastrointestinal dysfunction of sepsis (Review).Experimental and therapeutic medicine · 2022Review
- Nutrient niche specificity for glycosaminoglycans is reflected in polysaccharide utilization locus architecture of gutFrontiers in microbiology · 2022Article
- Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases.Biologics : targets & therapy · 2020Review
- Modulation of Intestinal Epithelial Glycocalyx Development by Human Milk Oligosaccharides and Non-Digestible Carbohydrates.Molecular nutrition & food research · 2019Article
- Galactosaminoglycans: Medical Applications and Drawbacks.Molecules (Basel, Switzerland) · 2019Review
- Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease.Frontiers in pharmacology · 2019Review
- New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease.Annals of translational medicine · 2017Review
- Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma.PloS one · 2017Article
- Heparanase: From basic research to therapeutic applications in cancer and inflammation.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2016Review
- Versatile role of heparanase in inflammation.Matrix biology : journal of the International Society for Matrix Biology · 2013Review
- Heparanase in inflammation and inflammation-associated cancer.The FEBS journal · 2013Review
- Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.Cellular and molecular life sciences : CMLS · 2012Review
- Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats.The Journal of biological chemistry · 2009Article
- The degradation of glycosaminoglycans by intestinal microflora deteriorates colitis in mice.Inflammation · 2009Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesChanges in extracellular matrix glycosaminoglycans (GAGs) of the intestinal mucosa have been associated with inflammatory bowel disease. The aim of the present study was to follow the changes in GAGs metabolism during the progression from non-inflamed to inflamed intestinal colon of patients with Crohn's disease (CD), using direct biochemical analysis and specific immunohistochemistry against chondroitin/dermatan sulfate and heparan sulfate. DESIGN AND
methodsThe content of GAGs from inflamed and non-inflamed colon of eight patients with active CD was estimated by uronic acid per dry weight of tissue and analyzed by agarose gel electrophoresis and ion-exchange chromatography. Intestinal sections were stained using antibodies against dermatan sulfate/chondroitin 4-sulfate (DS/CS), heparan sulfate (HS), and ICAM-1 (CD54), and analyzed by confocal microscopy.
resultsThere was a reduction in the amount of GAGs in the non-inflamed colon of patients with CD. In the inflamed colon, HS, CS and DS showed increased concentrations compared with the non-inflamed colon. GAGs showed a diffuse distribution in the lamina propria and in the basement membrane of both inflamed and non-inflamed mucosa of patients with CD.
conclusionWe observed a marked reduction in GAGs with altered patterns of distribution in the non-inflamed colon of patients with CD. The increase in the synthesis of GAGs observed in the inflamed colon may be a compensatory mechanism for the restoration of the integrity of the intestinal mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.